Boyd Taylor 4
4 · Avalo Therapeutics, Inc. · Filed Oct 6, 2025
Insider Transaction Report
Form 4
Boyd Taylor
Chief Business Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-10-01+275,000→ 275,000 totalExercise: $12.96Exp: 2035-10-01→ Common Stock (275,000 underlying)
Footnotes (1)
- [F1]The stock option was granted on October 1, 2025, and vests over four years, with the first 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to the reporting person's continued employment with the Company on each applicable vesting date.